oasis 1 semaglutide trial: Oral 50mg achieves 15.1% weight loss The Rise of Oral Obesity

Use caution in kidney disease, Pancreatitis history, gallbladder disease, Diabetic Retinopathy, pregnancy, or breastfeeding

As consumers' appetite for weight loss drugs continues to grow, many virtual care companies are jumping in to offer compounded GLP-1 medications as the branded drugs are often in short supply

The International Diabetes Federation projected that the number of diabetes cases is expected to reach 643 million by 2030 and 783 million by 2045

The way GLP-1s work has been well-established, but people are understandably concerned about some of the possible risks, such as the Ozempic muscle loss phenomenon

As a class effect, the benefits of these medications outweigh the risks, but their use warrants consideration of their potential sequelae